Megalabs North America’s Post

Galderma is on track for another strong year! The dermatology industry is booming, and Galderma is leading the way. In the first nine months of 2023, they achieved net sales of over 3 billion USD, driven by growth in all product categories. Of particular interest of course is Galderma's liquid botulinum toxin product - RelabotulinumtoxinA - a first in the market Results show the rapid onset of action with some patients reporting improvement as early as day one in trials. Durability is also a big factor with at least a third of patients rating their frown lines as ‘improved’ or better through to month 12 in one study. #Galderma #dermatology #innovation #financials #growth https://lnkd.in/gG9MJBGf

Galderma, a renowned pharmaceutical company specializing in dermatology, made headlines with its Initial Public Offering (IPO) as it debuted on the stock market. The company's IPO generated significant investor interest, reflecting confidence in its innovative products and strong market presence. On the first day of trading, Galderma experienced an impressive surge, with its stock price skyrocketing by 20%. Investors were drawn to Galderma's promising pipeline of dermatological treatments, which address a wide range of skin conditions, from acne to eczema. Additionally, the company's established reputation for quality and efficacy further fueled investor enthusiasm. The remarkable 20% increase in stock price on the inaugural trading day underscored the market's bullish sentiment towards Galderma's growth prospects and potential for delivering strong returns. This successful IPO marks a significant milestone for Galderma, signaling a new chapter of expansion and innovation in the field of dermatology. #Galderma #AdvancingDermatology #Dermatology #Healthcare #IPO

Skin Deep Solutions: Navigating the Prescription Dermatology Therapeutics Market 🩺💊 For Any Query, Click Here: https://shorturl.at/adluN Market Overview: The prescription dermatology therapeutics market witnessed a significant growth rate owing to high incidence and an increase in the prevalence rate of infectious and chronic dermatological disorders, and novel drug development across the world🌐🧴 Market Growth: Prescription Dermatology Therapeutics Market value is projected to reach US$ 72.27 Bn at the end of the forecast period and it is expected to grow at the CAGR of 9.5%. Witness the exponential growth of the Prescription Dermatology Therapeutics Market as it addresses various skin conditions and cosmetic concerns. From innovative topical treatments to biologic therapies, discover how the industry is not just treating skin disorders but also enhancing quality of life and promoting confidence. Join the conversation on the accelerating trends in dermatological therapeutics. 📈💉 Market Takeaways: Uncover the key takeaways shaping the future of the Prescription Dermatology Therapeutics Market. The rise of telemedicine in dermatology, the integration of digital tools for skin analysis, and the increasing demand for natural and sustainable skincare solutions are reshaping the industry. Stay informed about these trends to navigate the ever-evolving landscape of dermatological treatments. 🔄🧖♀️ Engage in the discussion! Share your experiences with prescription dermatology therapeutics, thoughts on skincare innovations, and ideas for promoting skin health and beauty. Let's collectively strive for healthier, more radiant skin through science-backed treatments! 💬🩺💄 #prescription #dermatology #therapeutics #market #skincare #bitcoin #pharmacy #healthylifestyle #medicine #skin #careforthecaregiver #business

How Dermatology Roll-Ups are a stable investment strategy for middle market private equity firms, especially in times of economic uncertainty The recent sale of NavaDerm Partners' New Jersey practices to Schweiger Dermatology Group (SDG) by Brown Gibbons Lang & Company (BGL) highlights a growing trend in the healthcare sector: dermatology roll-up strategies by Private Equity (PE) firms. NavaDerm and SDG: A Case Study in Dermatology Consolidation NavaDerm, a dermatology management platform based in New York City, was formed through the amalgamation of five dermatology groups in New York and New Jersey. With its focus on providing comprehensive dermatological services, including medical, surgical, and cosmetic procedures across its eight locations, NavaDerm has established itself as a significant player in the region. SDG, acquiring NavaDerm's practices, stands as the largest dermatology practice on the East Coast, boasting over 100 offices and more than 300 healthcare providers. This expansion not only strengthens SDG's market position but also exemplifies the strategic value of consolidating dermatology practices. The Appeal of Dermatology to Private Equity Dermatology presents an attractive proposition for PE firms due to several key factors: 1. Inelastic Demand: Dermatology services, both medical and cosmetic, enjoy a relatively inelastic demand, making them less susceptible to economic downturns. 2. Growth Potential: The continuous advancements in dermatological treatments and the rising public awareness about skin health fuel steady growth in this sector. 3. Operational Synergies: Consolidation enables operational efficiencies, cost savings, and enhanced service offerings. In contrast to more volatile sectors, dermatology offers a robust stability, thanks to the consistent demand for skin health services. This makes investments in dermatology practices particularly appealing for PE firms, especially in times of economic uncertainty where stable returns are highly valued. The sale of NavaDerm's New Jersey practices to SDG, facilitated by BGL, is a clear indicator of the lucrative nature of dermatology roll-up strategies for PE firms. This sector's resilience, driven by the inelastic demand for dermatological services and the potential for operational synergies, makes it a safe haven for investors seeking stable yet growth-oriented opportunities. As economic uncertainties loom, dermatology stands out as a beacon of stability in the healthcare investment landscape. https://lnkd.in/eV7C5zrc).

Stay ahead of the curve with this brand-new bi-weekly newsletter, "Dermatology.Business," designed specifically for marketers of dermatological Rxs, OTC products, devices, nutraceuticals, and other dermatology related services.   From the publishers of NPC Healthbiz Weekly and Skin Spectrum Weekly, "Dermatology.Business" leverages expertise in delivering valuable industry insights and dives deep into the latest industry buzz and trends. This newsletter is your go-to resource for: - Market trends in the dermatology sector - Competitive landscape analysis - Growth opportunities - Job postings   For companies aiming to reach key decision-makers in the Canadian pharmaceutical industry, they offer advertising and sponsorship opportunities. Showcase your products and services to a highly targeted audience of 1,450 pharmaceutical industry leaders across Canada every second Wednesday.   **Post dermatology industry jobs at no cost. ACT FAST! Space is limited**   Don't miss out on this essential resource for skincare industry leaders and innovators. Sign up for a free subscription at https://lnkd.in/gxATbms6

➡ Friday News! Thrilled to see Galderma's dedication to dermatology pay off with the FDA approval of Nemluvio for prurigo nodularis! This is a huge win for patients who struggle with the relentless itching and discomfort caused by this condition. Nemluvio, which blocks the IL-31 pathway—a key driver of itch and inflammation—has shown impressive results. In the Phase III OLYMPIA studies, over half of the patients treated with Nemluvio experienced a significant reduction in itch intensity, offering hope for better quality of life. What’s even more exciting is that this approval could be just the beginning. With Nemluvio also under FDA review for moderate-to-severe atopic dermatitis, a market with vast potential, Galderma is poised to make a big impact. Analysts are already predicting peak sales could reach $2.1 billion globally. As Galderma continues to push forward with additional regulatory reviews in Europe, Canada, and Australia, it’s clear that Nemluvio could become a game-changer in dermatology worldwide. Congratulations to everyone involved in bringing this innovative treatment to patients! #Dermatology #Galderma #Innovation #lifesciences #Pharma #headcounttag

The dermatology segment in the Indian Pharmaceutical Market is expected to grow at 11-12%. Banking on this, top performers in this segment are focusing on new product launches and science-based solutions.

Today marks the launch of Dermatology.Business, a biweekly newsletter crafted specifically for marketers of dermatological Rxs, OTC products, devices, nutraceuticals, and services. Our inaugural edition dives deep into the latest industry buzz, asking the pivotal question: "Now that Apotex Inc. has acquired Blexten-maker Searchlight Pharma Inc., could more dermatology acquisitions be on the horizon?" But that ain't all. We also explore: - The booming laser market - A major merger in the CMO space - Challenges faced by psoriasis patients - Current career opportunities for derm marketers Don't miss out on this essential resource for skincare industry leaders and innovators. Sign up for a free subscription at https://lnkd.in/gxATbms6 and grab your copy of issue number one, destined to be a collector's item. Dermatology.Business is something new from Chronicle Companies, creators of the National Pharmaceutical Congress, Skin Spectrum Summit, and many other media platforms for #HCPs and the #life_sciences sector. #Dermatology #Pharma #Marketing #Newsletter #BusinessNews #skinhealthforall #purposedrivendermatology #ideas in the #service of #medicine

The global Dermatology Diagnostic and Therapeutic Devices market was valued at US$ 13240 million in 2023 and is anticipated to reach US$ 21260 million by 2030 witnessing a CAGR of 7.0% during the forecast period 20242030. According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #DermatologyDevices #SkinCare #SkinDisease #DermatologyMarket #HealthcareTechnology #SkinTreatment #DermatologyResearch #SkinHealth #MedicalDevices #GlobalMarket

Strategic Partnerships are central to the success of any firm.